1 / 10


Pharmacogenomics. Jatinder Lamba Associate Professor Experimental and Clinical Pharmacology College of Pharmacy. Moderate or poor response. “One size doesn’t fit all” : Inter-individual variability in response. Good Response No adverse effects. All Patients with Same Diagnosis.

Télécharger la présentation


An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.


Presentation Transcript

  1. Pharmacogenomics Jatinder LambaAssociate Professor Experimental and Clinical Pharmacology College of Pharmacy

  2. Moderate or poor response “One size doesn’t fit all” : Inter-individual variability in response Good Response No adverse effects All Patients with Same Diagnosis Increased toxicity risk

  3. No drug is safe and effective in a same way for everyone Spear et al, 2001

  4. Variation is the spice of life • Human genome has 3.2 billion base pairs • Any two genomes are 99.9 % identical • 0.1% => every two genomes have 3.2 million differences IHGSC. Nature (2001) 409 860-921

  5. Pharmacogenetics/genomics How inherited genetic differences influence treatment response to drugs Pharmacology + Genetics Key is to understand to what degree genetics is valuable to a given disease/therapy AND use this information to • Avoid adverse drug reactions • Maximize therapeutic efficacy • Preselect responsive/nonresponsive patients and tailor therapy accordingly

  6. http://www.pharmacy.umn.edu/puma-ipm/

  7. PUMA-Research Group

  8. Ongoing Pharmacogenomic Projects (Lamba Lab) • Pharmacogenomics and PharmacoEpigenomics of nucleoside analogs in AML patients (NIH funded). • PGx of antibody targeted therapy in pediatric AML (NIH funded). • PGx of platinating agents and taxanes in ovarian and lung cancer patients. • PGx of cyclophosphamide in BMT patients.

  9. There is little difference between human and veterinary species in regard to the magnitude of inter-subject variability in drug pharmacokinetics and pharmacodynamics. • Despite the lack of genetic information in veterinary medicine, breed specific differences in response to endogenous and exogenous substances have been reported across a range of species, including cattle (1), sheep (2), chickens (3), pigs (4), and dogs.

  10. Thank You

More Related